SwePub
Sök i LIBRIS databas

  Extended search

(WFRF:(Eden Engström Britt)) pers:(Berinder Katarina) lar1:(umu)
 

Search: (WFRF:(Eden Engström Britt)) pers:(Berinder Katarina) lar1:(umu) > Long-term Follow-up...

Long-term Follow-up of 84 Patients With Giant Prolactinomas-A Swedish Nationwide Study.

Himonakos, Christos (author)
Karolinska Institute,Karlstad Hospital,Karolinska Inst, Dept Mol Med & Surg, S-17176 Stockholm, Sweden.;Karlstad Cent Hosp, Ctr Endocrinol & Diabet, Dept Internal Med, S-65185 Karlstad, Sweden.;Karlstad Cent Hosp, Ctr Endocrinol & Diabet, Dept Internal Med, Rosenborgsgatan 9, S-65185 Karlstad, Sweden.
Burman, Pia (author)
Lund University,Lunds universitet,Translationell muskelforskning,Forskargrupper vid Lunds universitet,Translational Muscle Research,Lund University Research Groups,Skåne University Hospital,Lund Univ, Skane Univ Hosp, Dept Endocrinol, S-21428 Malmö, Sweden.
Borg, Henrik (author)
Lund University,Lunds universitet,Medicin/akutsjukvård, Lund,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Medicine, Lund,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital,Lund Univ, Skane Univ Hosp, Dept Endocrinol, S-22242 Lund, Sweden.
show more...
Dahlqvist, Per (author)
Umeå University,Umeå universitet,Institutionen för folkhälsa och klinisk medicin,Umeå Univ, Dept Publ Hlth & Clin Med, S-90187 Umeå, Sweden.
Edén Engström, Britt (author)
Uppsala universitet,Endokrinologi och mineralmetabolism,Uppsala University Hospital, Uppsala, Sweden
Ekman, Bertil (author)
Linköping University,Linköpings universitet,Avdelningen för diagnostik och specialistmedicin,Medicinska fakulteten,Region Östergötland, Endokrinmedicinska kliniken,Linköping Univ, Dept Endocrinol, S-58183 Linköping, Sweden.;Linköping Univ, Dept Hlth Med & Caring Sci, S-58183 Linköping, Sweden.
Emilsson, Louise (author)
Karolinska Institutet,Karolinska Institute,University of Oslo,Univ Oslo, Inst Hlth & Soc, Dept Gen Practice, N-0318 Oslo, Norway.;Cty Council Varmland, Nysater Hlth Care Ctr, S-65185 Karlstad, Sweden.;Cty Council Varmland, Ctr Clin Res, S-65185 Karlstad, Sweden.;Karolinska Inst, Dept Med Epidemiol & Biostat, S-17177 Stockholm, Sweden.
Olsson, Daniel S, 1983 (author)
Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för invärtesmedicin och klinisk nutrition,Institute of Medicine, Department of Internal Medicine and Clinical Nutrition,Department of Endocrinology at Sahlgrenska University Hospital, Gothenburg, Sweden; Department of Internal Medicine and Clinical Nutrition, Institute of Medicine at Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden,Sahlgrens Univ Hosp, Dept Endocrinol, S-41345 Gothenburg, Sweden.;Univ Gothenburg, Sahlgrenska Acad, Inst Med, Dept Internal Med & Clin Nutr, S-41345 Gothenburg, Sweden.;AstraZeneca, BioPharmaceut R&D, Cardiovasc Renal & Metab, S-43051 Gothenburg, Sweden.
Ragnarsson, Oskar, 1971 (author)
Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för invärtesmedicin och klinisk nutrition,Institute of Medicine, Department of Internal Medicine and Clinical Nutrition,Department of Endocrinology at Sahlgrenska University Hospital, Gothenburg, Sweden; Department of Internal Medicine and Clinical Nutrition, Institute of Medicine at Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden,Sahlgrens Univ Hosp, Dept Endocrinol, S-41345 Gothenburg, Sweden.;Univ Gothenburg, Sahlgrenska Acad, Inst Med, Dept Internal Med & Clin Nutr, S-41345 Gothenburg, Sweden.
Wahlberg, Jeanette, 1969- (author)
Örebro University,Örebro universitet,Institutionen för medicinska vetenskaper,Department of Medicine, Örebro University Hospital, Sweden; School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Sweden,Örebro Univ Hosp, Dept Med, S-70185 Örebro, Sweden.;Örebro Univ, Fac Med & Hlth, Sch Med Sci, S-70182 Örebro, Sweden.
Åkerman, Anna-Karin (author)
Karolinska Institutet,Karolinska Institute,Örebro University Hospital,Karolinska Inst, Dept Mol Med & Surg, S-17176 Stockholm, Sweden.;Örebro Univ Hosp, Dept Med, S-70185 Örebro, Sweden.
Höybye, Charlotte (author)
Karolinska Institutet,Karolinska Institute,Karolinska University Hospital,Karolinska Inst, Dept Mol Med & Surg, S-17176 Stockholm, Sweden.;Karolinska Univ Hosp, Dept Endocrinol, S-17176 Stockholm, Sweden.
Berinder, Katarina (author)
Karolinska Institutet,Karolinska Institute,Karolinska University Hospital,Karolinska Inst, Dept Mol Med & Surg, S-17176 Stockholm, Sweden.
show less...
 (creator_code:org_t)
Oxford University Press, 2023
2023
English.
In: The Journal of clinical endocrinology and metabolism. - : Oxford University Press. - 1945-7197 .- 0021-972X. ; 108:12
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • To describe the clinical presentation and treatment outcomes in a nationwide cohort of patients with giant prolactinomas.Register-based study of patients with giant prolactinomas [serum prolactin (PRL) > 1000 µg/L, tumor diameter ≥40 mm] identified in the Swedish Pituitary Register 1991-2018.Eighty-four patients [mean age 47 (SD ±16) years, 89% men] were included in the study. At diagnosis, the median PRL was 6305 µg/L (range 1450-253 000), the median tumor diameter was 47 mm (range 40-85), 84% of the patients had hypogonadotropic hypogonadism, and 71% visual field defects. All patients were treated with a dopamine agonist (DA) at some point. Twenty-three (27%) received 1 or more additional therapies, including surgery (n = 19), radiotherapy (n = 6), other medical treatments (n = 4), and chemotherapy (n = 2). Ki-67 was ≥10% in 4/14 tumors. At the last follow-up [median 9 years (interquartile range (IQR) 4-15)], the median PRL was 12 µg/L (IQR 4-126), and the median tumor diameter was 22 mm (IQR 3-40). Normalized PRL was achieved in 55%, significant tumor reduction in 69%, and combined response (normalized PRL and significant tumor reduction) in 43%. In the primary DA-treated patients (n = 79), the reduction in PRL or tumor size after the first year predicted the combined response at the last follow-up (P < .001 and P = .012, respectively).DAs effectively reduced PRL and tumor size, but approximately 1 patient out of 4 needed multimodal treatment. Our results suggest that the response to DA after 1 year is useful for identifying patients who need more careful monitoring and, in some cases, additional treatment.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Kirurgi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Surgery (hsv//eng)

Keyword

Male
Humans
Middle Aged
Female
Prolactinoma
drug therapy
pathology
Pituitary Neoplasms
therapy
drug therapy
Follow-Up Studies
Sweden
epidemiology
Prolactin
Dopamine Agonists
therapeutic use
giant prolactinomas
dopamine agonist resistance
dopamine agonists
giant prolactinomas
Ki-67
long-term follow-up

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view